Who is sponsoring NCT05581134?

NCT05581134 is sponsored by Marialuisa Gandolfi.

What drugs are being tested in NCT05581134?

Interventions in NCT05581134: Virtual Reality intervention, Control Group intervention.

What condition does NCT05581134 study?

NCT05581134 studies Functional Motor Disorders.

Is NCT05581134 still recruiting?

NCT05581134 is currently status unknown. Last updated 14 October 2022.

Last reviewed 2022-10-14 · How we verify

NCT05581134: FMD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immersive Virtual Reality in Functional Motor Disorders

Status unknown NA Last updated 14 October 2022

What this trial tests

NA trial testing Virtual Reality intervention in Functional Motor Disorders in 36 participants. Status unknown.

Timeline

29 September 2022

Primary endpoint
30 August 2023

29 September 2023

Quick facts

Lead sponsor	Marialuisa Gandolfi
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	36
Start date	29 September 2022
Primary completion	30 August 2023
Estimated completion	29 September 2023
Sites	1 location across Italy

Drugs / interventions tested

Virtual Reality intervention
Control Group intervention

Conditions studied

Functional Motor Disorders — all drugs for Functional Motor Disorders →

Sponsor

Marialuisa Gandolfi

Who can join

18 and older, any sex, with Functional Motor Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to demonstrate the effectiveness and superiority of a 5-day immersive VR-rehabilitation treatment versus a 5-day conventional rehabilitation treatment in reducing FMDs symptoms severity, assessed by the Simplified Functional Movement Disorders Rating Scale (S- FMDRS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

How Does Postural Control in Patients with Functional Motor Disorders Adapt to Multitasking-Based Immersive Virtual Reality?
Gandolfi M, Sandri A, Menaspà Z, Avanzino L, et al · · 2024 · cited 2× · PMID 38178646 · DOI 10.1002/mdc3.13961

Verify or expand the search:

Other trials of Virtual Reality intervention

Trials testing the same drug.

NCT07470697 — Deep Relaxation Using Virtual Reality Intervention Before Surgery for Healthcare Professionals Working in the Operating · NA · not yet recruiting
NCT07155681 — Evaluating Healthcare Professionals' Satisfaction and Stress Mitigation Using Virtual Reality Intervention in Surgical W · NA · not yet recruiting
NCT06922838 — The Effectiveness of a Virtual Reality-based Multisensory Intervention · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05581134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marialuisa Gandolfi
Last refreshed: 14 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05581134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing